Invokana Lawsuit and FDA Bone Fracture Warnings Prompt A Closer Look At SGLT2 Inhibitors

February 12, 2016 – – TheProductLawyers.com reports on a recent warning from the U.S. Food and Drug Administration (FDA) which states that type-2 diabetes drugs Invokana and Invokamet may decrease the bone density of those taking it, increasing their risk of suffering bone fractures. Although the information provided with the drug has always indicated a potential bone fracture risk, the FDA has found it necessary to add a new warning recently, which, among other things, notes that bone fractures are more common in patients who take Invokana when compared to those taking a placebo pill.

Statements from the FDA noted, “Fractures were observed as early as 12 weeks after treatment initiation, and were more likely to be low trauma (e.g., arising after falls from no more than standing height) and affect the upper extremities.” This commentary appears to indicate that fractures could occur quite easily for those using the drug.

The FDA also discussed an observed decrease in overall bone mineral density. To establish this, the organization looked at a study which evaluated 714 elderly patients. Those who took Invokana showed increased bone loss in their hip and spine areas, and, those who took higher doses of Invokana suffered additional bone loss.

Invokana’s link to bone loss, (as well as a common bone loss link to other SGLT2-inhibitor drugs) has been something that the FDA has studied for several years now. The Endocrinologic and Metabolic Drugs Advisory Committee also issued a warning regarding bone fractures observed after clinical trials on the drug in 2013.

The FDA has issued other warnings regarding Invokana recently. The drug has also been linked to the development of diabetic ketoacidosis, urinary tract infections, heart attacks, kidney failure, and strokes. Recent diabetic ketoacidosis warnings have been the subject of several Invokana lawsuits, as they describe a dangerous and life-threatening condition in which the body’s bloodstream contains too much acid.

The attorneys at Banville Law, who provide additional resources concerning Invokana on TheProductLawyers.com, understand the seriousness of the conditions recently linked to SGLT2 inhibitors. Currently, they are working to help ensure that anyone who has used these types of diabetes drugs and who has later suffered from adverse health events will have the opportunity to fully evaluate their legal rights. In addition, the attorneys of Banville Law are offering complimentary consultations to those who believe they were negatively affected by using Invokana to treat their type 2 diabetes.

To request additional information, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60008098